Biogen to Present New Alzheimer's Data at CTAD 2024, Highlighting Lecanemab and AI Insights
核心洞察
Biogen will present new data from its Alzheimer's portfolio at the CTAD conference in Madrid, focusing on treatment and preclinical research.
Key presentations will feature lecanemab treatment in clinical practice and the design of the AHEAD 3-45 study for preclinical Alzheimer's.
The company will also present data on AI-derived prognostic covariates to enhance the precision of lecanemab efficacy assessments.
Biogen (BIIB) is set to present new scientific findings from its Alzheimer's portfolio at the Clinical Trials on Alzheimer's Disease (搜索) (CTAD) annual conference in Madrid, Spain, from October 29 to November 1. The presentations will cover various aspects of Alzheimer's treatment, including data on lecanemab, preclinical research, and the use of AI-derived prognostic covariates. These data underscore Biogen's commitment to advancing Alzheimer's research and treatment.
Lecanemab Treatment and Clinical Practice
Several presentations will focus on lecanemab (LEQEMBI), a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody, in clinical practice. LEQEMBI is indicated for the treatment of Alzheimer’s disease and should be initiated in patients with mild cognitive impairment or mild dementia. Presentations include:
- Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from an Alzheimer's Disease Treatment Center, Tuesday, October 29
- Does the Current Evidence Base Support Continued Dosing with Lecanemab for Early Alzheimer's Disease? Wednesday, October 30, 9:40 AM
- Lecanemab for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adults That Are Apoliprotein E ɛ4 Heterozygotes or Non-Carriers, Wednesday, October 30, 11:20 AM
- One-Year Experience on the Use of Lecanemab in Clinical Practice, Wednesday, October 30, 3:30 PM
AHEAD 3-45 Study Design
The AHEAD 3-45 study design, a novel screening process for a preclinical AD trial, will also be a key presentation. This study aims to identify individuals at risk of developing Alzheimer's disease (搜索) before the onset of significant cognitive decline. The presentation is scheduled for Tuesday, October 29, at 6:10 PM.
AI-Derived Prognostic Covariates
Biogen will present data on AI-derived prognostic covariates that enhance the precision of lecanemab efficacy assessments and optimize Alzheimer's disease (搜索) clinical trials. This presentation, scheduled for Thursday, October 31, at 3:25 PM, highlights the use of artificial intelligence to improve the efficiency and accuracy of clinical trials.
Virtual Experience on Tau Pathology
In addition to the presentations, Biogen will host a virtual booth exploring the role of tau (搜索) in Alzheimer’s disease. The booth will feature an interactive medical education e-learning module on knowtau.com, providing more information on tau pathophysiology.
Commitment to Alzheimer's Research
Priya Singhal, M.D., M.P.H., Head of Development at Biogen, stated, "These data showcase the breadth of our Alzheimer’s disease research and our ongoing commitment to scientific innovation. We remain dedicated to advancing the field of research and treatment for this disease in order to better serve the millions of patients, families and providers in the Alzheimer’s community."
Biogen's presentations at CTAD 2024 reflect its ongoing efforts to address the challenges of Alzheimer's disease (搜索) through innovative research and treatment strategies.